The Orphan Drug Designation strengthens LP-284’s clinical development path and provides the opportunity for additional market exclusivity and commercial protection.
Lantern is anticipating filing the IND with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in B-cell non-Hodgkin’s lymphomas (NHL), including mantle cell lymphoma (MCL), by mid 2023.
In the US, MCL is diagnosed in approximately 4,500 patients each year and has an estimated annual market potential of $600 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.